Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
Stockholm, Sweden – August 7, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical stage biotech company specializing in the development of innovative anti-fungal therapies, today announced the acceptance of an abstract for oral presentation by the Company’s Chief Operating Officer Tine Kold Olesen, PhD, MBA, at the 11th Congress on Trends in Medical Mycology (TIMM-11) to take place in Athens, Greece, from October 20-23, 2023.This abstract will feature the clinical data obtained from the recently completed Phase 1 clinical trial evaluating the safety, tolerability, and